If this thing can tell me when I left my wedge on the previous hole. I’m in for $3k

Chiefs Accused Of Rigging Games By Playing Better Than The Other Teams buff.ly/3WDKaOS

Sunday's must watch game was watched by all 🍿 (via Austin Karp)

🔬 New insights on heart failure treatment! 🫀 My presentation to Cardiovascular Research Foundation #THT2025 this week. Our real-world study using Truveta™ data shows Cardiac Contractility Modulation (CCM) offers comparable survival to CRT in NYHA III patients. 📊 Key findings: ✔️ 76% survival

AP, better triple-check your ABG values— InterQual and Coding Queries are going to nitpick if this was really respiratory failure vs. insufficiency

Now published in CircInterventions, our paper on AltaValve transcatheter mitral valve replacement for atrial functional mitral regurgitation. A short🧵 ahajournals.org/doi/10.1161/CI…

New Pope claims to be a true Chicago Cubs fan, but internet photos show him wearing a Cardinal’s uniform I have the receipts

New in Circulation: #HFC members review the use of patient-reported outcomes (PROs) in #heartfailure trials. Butler et al. outline key challenges—tool selection, timing, meaningful change, and stats—that must be addressed for wider PRO adoption in research and care.

Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions Latest review article with my colleagues Drs. Andrew Girard and Talal Asif pubmed.ncbi.nlm.nih.gov/40147532/

🚨Two new JACC Advances papers drop today linking SGLT2 inhibitors ↔ apolipoprotein M (ApoM) across very different settings—ambulatory HFrEF (DEFINE-HF) and acute inflammation (LPS-sepsis & COVID-19). Let’s unpack why this kidney-liver-vascular axis matters. A 🧵 1️⃣/15

When patients pick up their Eliquis, Bristol Meyers is going to pay them $1000?

MAPLE HCM presented by Pablo Garcia-Pavia #ESC2025 #cardiotwitter

NEJM Paper nejm.org/doi/full/10.10…

Late RV failure after LVAD? Most run the other way. Not Lisa Jennings. 💪 One of the few bold enough to face it head-on — and patients are better for it. #HFSA #HeartFailure

Wrapping up #HFSA2025 with a Taylored approach to CHF Fittingly being presented by KC boy Michael Nassif See y’all in 2026. Long live all the magic we made 🫶 Taylor Swift Travis Kelce Saint Luke's Mid America Heart Institute HFSA Andrew J Sauer MD Brett Sperry, MD EmilyPowell Nosheen Reza, MD, MS Alexander Hajduczok, MD 🇺🇦🙏

Cardiac Imaging Fellowship at Saint Luke's Mid America Heart Institute in KC available next year for interested applicants! 1yr fellowship with a focus on your modalities of interest - PET, CCTA, CMR, echo/structural Apply below! saintlukeskc.org/education/resi…

Welcoming Dr. James Januzzi as the Arvin Gottlieb Visiting Professor We at Saint Luke's Mid America Heart Institute were honored to host our friend and colleague, Dr. James L. Januzzi, MD, as our Arvin Gottlieb Visiting Professor. His Grand Rounds—“The Evolution of Cardiac Biomarker Testing”—was a

Grateful for assigned Discussant role for #AHA25 Late-Breaking Science on Sun Nov 8 — DAPA ACT HF-TIMI 68 BP & SOTA-P-CARDIA. Fresh data, practical takeaways, and what we do next. Bring your questions and join the dialogue.

#AHA25: In this PRO analysis of MAPLE-HCM, aficamten monotherapy was more effective than metoprolol in improving health status, including changes in the KCCQ and SAQ scores. Learn more: bit.ly/4hK858o Michael Nassif #HCM #cvHCM

Aficamten vs metoprolol responder analysis. How many more trials in oHCM and myosin inhibition are needed prior to establishing LVOT gradients/LVEF, (supported by NTproBNP and safety) as the outcome? Placebo effect on NYHA/KCCQ is sizable, while pVO2 continues to provide a